Benitec Biopharma Inc.

NasdaqCM BNTC

Benitec Biopharma Inc. Price to Sales Ratio (P/S) on January 14, 2025: 40,164.37

Benitec Biopharma Inc. Price to Sales Ratio (P/S) is 40,164.37 on January 14, 2025, a 14,593.88% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Benitec Biopharma Inc. 52-week high Price to Sales Ratio (P/S) is 51,465.14 on December 31, 2024, which is 28.14% above the current Price to Sales Ratio (P/S).
Benitec Biopharma Inc. 52-week low Price to Sales Ratio (P/S) is 261.21 on February 14, 2024, which is -99.35% below the current Price to Sales Ratio (P/S).
Benitec Biopharma Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 14,390.06.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: BNTC

Benitec Biopharma Inc.

CEO	Dr. Jerel A. Banks M.D., Ph.D.
IPO Date	June 24, 2014
Location	United States
Headquarters	3940 Trust Way
Employees	16
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Key trends

Past 5 years